ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Mar 24, 2018
Archive: Nelson's "Off the Cuff" Video Series
Image: President of Investment Research Brian Nelson. We hope you enjoyed the "Off the Cuff" video series, where President of Investment Research at Valuentum Brian Nelson talked in front of the camera for about 10 minutes each episode! The videos were purposely designed to be low-tech, we know - we call this "authen-tech." We like that, and you should, too. These are not instructional videos. They are meant to be energetic, exciting, and a bit controversial. Nelson tells it how it is. That's the only way. Videos filmed December and January 2017/2018. Follow up reading/videos provided.
Mar 21, 2018
General Mills' Dividend Is Now of Questionable Health
General Mills is stuck between a rock and a hard place, and the market is finally noticing. Its best dividend growth years have been behind it, but its recent dealings have put it in a rather precarious position heading into the next recession, the timing of which is the only uncertainty. The company has never been a consideration for inclusion in the simulated Dividend Growth Newsletter portfolio.
Mar 20, 2018
Avoiding Troubled Equities Such as General Electric
The Valuentum process waits for a stock’s price to be moving higher before it is considered. The stock must not only be undervalued on both a discounted cash-flow basis and relative value basis, in our view, but the market must also believe that its true intrinsic value should be higher, too, as evidenced by a rising share price. The process is symmetrical. We also would wait for a company’s share price to break down before we may consider removing an overpriced stock. In some cases, the information contained in prices can even provide clues when to remove an underpriced stock, as in the case of General Electric.
Mar 16, 2018
Saying Good Bye to Boeing…For Now
There probably hasn’t been a better large-cap call in the Dow Jones Industrial Average than Boeing during the past couple years, and we have been all over it. But shares have now “rolled over,” and its valuation isn’t as attractive as it once was, both dynamics pointing to reasons for removal from the simulated Dividend Growth Newsletter portfolio. We continue to peruse our coverage universe for an adequate dividend growth replacement.
Mar 13, 2018
Our Ideas Are Performing Awesome So Far in 2018!!! 6 of the Top 7 of the Dow!
We’ve done a fantastic job identifying some of the top performers in the Dow Jones Industrial Average during 2018 (6 of the top 7!), but to be fair, a couple haven’t panned out that well either. In any case, we couldn’t be more pleased with the simulated newsletter portfolio ideas.
Mar 13, 2018
Don’t Just Look at the House; Examine the Foundation
Image Source: Lindsay Holmwood. Let’s examine how we derive the forecasts in our stock and dividend reports. "Buying a stock after reading an article without examining its valuation model is like buying a house without examining the foundation." -- The Valuentum Team
Mar 12, 2018
The "Luck" and "Randomness" of Index Funds
If the year-to-year performance of active funds relative to index funds can be considered “random,” so then is the year-to-year performance of index funds relative to active funds, regardless of fees and expenses. Image shown: page 1 of 14.
Mar 8, 2018
A Little Optimization To Maximize The Value
We continue to help readers find some of our best ideas for consideration, and some of the companies in this article didn’t make the cut for our long-term perspective. We’re allocating resources elsewhere.
Mar 7, 2018
Protectionists Gaining Control, Implications on Europe and China
It looks like the US-imposed tariffs are moving forward, and we’re starting to hear chatter about retaliation from Europe. Could China be next? Canada and Mexico may be exempt from the tariffs, however.
Mar 6, 2018
Updating Our Thoughts on Celgene
Image Source: Celgene. Although the combination of disruptive new discoveries coupled with burgeoning demand thanks to the aging demographics of the world’s population sets the biotech space for a potential virtuous long-term cycle, we’re not too happy with with the recent developments at Celgene. Let’s dig in.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.